Multiple Myeloma Hub
Subscribe in ParasocialFree on the App Store for iPhone, iPad and Mac. No subscription needed. Once it is installed, tap this link again and the show is yours. Already have it? Open in Parasocial.
About
The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in multiple myeloma. Our aim is to enhance knowledge in multiple myeloma, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management. Hosted on Acast. See acast.com/privacy for more information.
Also on
Recent episodes
- How is belantamab mafodotin currently used in clinical practice for MM?
- How are ocular toxicities associated with belantamab mafodotin managed in MM?
- Targeting FcRH5 in MM: Rationale and emerging dual-targeting strategies
- IMS 2026 | CARTITUDE-2 Cohort A: ≥5-year remission and survival with cilta-cel in RRMM
- IMS 2026 | UKMRA ProMMise D interim results: VRAT-guided belantamab mafodotin dosing in RRMM
- How to optimize outpatient delivery of bispecific antibody therapy for MM
- Belantamab mafodotin in RRMM: Latest updates and practical considerations
- How to manage toxicities associated with bispecific antibody therapy for MM in community practice
- How to transition patients to community-based bispecific antibody therapy
- EHA2026 | DREAMM-8: Early RRMM and sustained MRD-negativity subgroup analyses